Alkermes shares are trading higher after positive topline results from the phase 3 REVITALYZ study of LUMRYZ for excessive daytime sleepiness associated with idiopathic hypersomnia. The readout is a meaningful clinical positive for the company’s neuroscience franchise and supports the drug’s commercial prospects. The move is likely to affect ALKS shares more than the broader market.
Alkermes shares are trading higher after positive topline results from the phase 3 REVITALYZ study of LUMRYZ for excessive daytime sleepiness associated with idiopathic hypersomnia. The readout is a meaningful clinical positive for the company’s neuroscience franchise and supports the drug’s commercial prospects. The move is likely to affect ALKS shares more than the broader market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
